Open in interactive viewer → charts, metric popovers & call review

IceCure: Four Sites, $8.2 Million, and a Deadline That Quietly Moved

U.S. sales rose 83% and the commercial map doubled to 21 states — but the ChoICE study slipped a third time, the 400-patient goal turned conditional, and the word CPT never came up.
ICCM · Earnings Call · 2026-11-18

IceCure: Four Sites, $8.2 Million, and a Deadline That Quietly Moved

The valuation is the story before the story

IceCure Medical is a $1.9 million market-cap medical device company that finished September with $8.2 million in cash. Read that again: the equity is valued below the cash on the balance sheet. Whatever the operating narrative says, that spread is the market's verdict — the cash is spoken for. And the burn explains why. The first nine months of 2026 produced a $12.9 million operating loss against $2.6 million of revenue, with R&D at $6.5 million (up from $5.1 million on ChoICE post-marketing study costs) and sales and marketing at $3.6 million. Run that arithmetic forward from $8.2 million and you do not need a model to see the financing question sitting in the room, unasked by any analyst on the call. The top line itself is genuinely improving: revenue up 26% to $2.6 million, gross profit up 22% to $762,000. But this is a company where the growth rate and the absolute dollar are two very different facts.

The commercial build is real, and it is small

Credit where due. IceCure nearly doubled its commercial footprint from 11 states at the end of Q2 2025 to 21 states, adding reps in New York, Southern California, the Midwest and Florida. U.S. sales rose 83% year-over-year for the nine months, and VP of North America sales Shad Good was the most expansive voice on the call: “We feel like we're starting to get some real traction here in the U.S. and also getting some momentum with that.” — Shad Good, Vice President Sales, North America · 2026-11-18 Internationally, there is a China regulatory approval and an exclusive Netherlands distribution deal, though the China go-to-market is still a conversation rather than a contract — “We are now in discussions with some potential partners, mainly more as a mode of distribution.” — Eyal Shamir, Chief Executive Officer · 2026-11-18 Health Canada is framed as two to four months out, and Terumo's Japan PMDA submission as first-half 2027. Forward guidance, such as it is, is one phrase from CFO Meir Peleg: “the projection for next year for revenue is a healthy double-digit growth.” — Meir Peleg, Chief Financial Officer · 2026-11-18 He also confirmed the seasonality that makes Q3 the softest quarter — meaning the reported period was the weakest of the year by the company's own framing, and Q4 must carry the year.

A study that keeps slipping, and a target that just went conditional

This is where the report earns its attention. In May 2026 the company told investors the first ChoICE patient would be enrolled before September 5, per the FDA protocol: “before September 5, as the FDA approved the protocol by March 5. We will have the first patient, and we expect and plan to complete 80 patients before March 2027.” — Eyal Shamir, CEO · 2026-05-12 By the August call the language had hardened into confidence: “Yes. Yes, with a high confidence that we will be able to meet. We need to meet the first patients before September 1st.” — Eyal Shamir, CEO · 2026-08-12 In November, the first patients were treated in October — a miss — and the site base stands at four, not the thirty the protocol contemplates. Good was refreshingly blunt: “We're currently at four sites as of today, but we're expecting to finalize some additional sites here in the very near future.” — Shad Good, Vice President Sales, North America · 2026-11-18 Note also the small internal seam: prepared remarks named three clinical sites, while the Q&A said four. Then came the number that matters. Asked directly whether the 80-by-March-2027 and 400-by-March-2029 milestones were on track, CEO Eyal Shamir addressed only the far one:

I am not sure that we will be able to do the 400 within the three years, because some of the contracts, agreements, some of the sites is taking them longer time.

Eyal Shamir, Chief Executive Officer · 2026-11-18
And when an analyst offered the obvious escape hatch — asking whether the company could go back to the FDA for an extension — the answer was yes, framed as routine: continuous communication, mutual agreement. That is a company pre-positioning for a timeline reset on the single piece of evidence generation that underpins its broader adoption thesis. The 80-patient target, notably, went unaddressed.

What management stopped saying

The loudest signal on this call is an absence. For four straight quarters, the CPT-1 reimbursement code was the load-bearing wall of the IceCure story — the thing that turns a $4,000-per-procedure device from a cash-pay curiosity into a standard of care. In March 2026 the CEO was explicit that CPT-1 was the inflection point: “we believe that our next coming inflection point will be early 2028 after we get the CPT1.” — Eyal Shamir, Unknown (likely Executive) · 2026-03-17 On this call, CPT did not appear — not in prepared remarks, not in any analyst question, not in the closing priorities. For a company whose commercial argument runs through office-based, out-of-pocket reimbursement, that silence is louder than any guidance cut would have been. The same pattern shows up on the installed base. In August the CEO volunteered that active U.S. sites were “above 30, 3-0 sites, Altogether.” — Eyal Shamir, CEO · 2026-08-12 In November, asked the identical question, the answer became: “We are not giving guidance... I believe that in few weeks or months or two, we will give some update information of that.” — Eyal Shamir, Chief Executive Officer · 2026-11-18 When the number that used to be given freely becomes a deferral, the number has usually stopped flattering.

The read

There is no sector wave carrying this name. A scan of the broader market's price movers over the last quarter shows capital rotating through power, data-center and mining themes and through the healthcare-adjacent site of service and ambulatory surgery center complexes — none of which has anything to do with breast cryoablation. IceCure is a company-unique story: a legitimately growing U.S. franchise at a revenue base small enough that the entire year's sales would not cover five weeks of operating burn, a clinical evidence program moving at four sites against a thirty-site design, and a reimbursement catalyst that has slipped out of the narrative entirely. The bull case still exists and it is not stupid — 83% U.S. growth, a doubled field force, approvals stacking up in China, the Netherlands, Canada and eventually Japan. But the equity is priced beneath its own cash, and the call that was supposed to steady the ship instead moved the goalposts and went quiet on the one topic investors most needed to hear about.